90Y-DOTA-TYR3-OCTREOTIDE ADMINISTERED TO CHILDREN WITH REFRACTORY TUMORS

90Y-DOTA-TYR3-奥曲肽治疗难治性肿瘤儿童

• 批准号: 7604807
• 负责人: M. Sue O'Dorisio
• 金额: $ 0.39万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604807
• 关键词: Child; Computer Retrieval of Information on Scientific Projects Database; Ewings sarcoma; Family; Funding; Grant; Institution; Neuroblastoma; Octreotide; Refractory; Research; Research Personnel; Resources; Solid Neoplasm; Somatostatin Receptor; Source; United States National Institutes of Health; medulloblastoma; sarcoma; therapeutic target; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study hypothesizes that somatostatin receptors can be exploited as a therapeutic target in the subset of neuroblastoma, medulloblastoma, the Ewing's sarcoma family of tumors and ostegenic sarcoma solid tumors that can be demonstrated to express somatostatin receptors.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究假设生长抑素受体可以作为神经母细胞瘤、髓母细胞瘤、尤文肉瘤家族肿瘤和骨肉瘤实体瘤的治疗靶点，这些肿瘤可以被证明表达生长抑素受体。